Search results for "Thromboplastin"

showing 10 items of 49 documents

Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma.

1995

Abstract A fully mechanized chromogenic substrate assay method for the rapid and specific determination of recombinant hirudin (r-hirudin) in citrated plasma on clinical chemistry analyzers (Hitachi 911 and Cobas Mira) is described. In a first step, 12 μl sample volume is mixed with the chromogenic substrate. Due to the almost immediate action of hirudin the inhibitory reaction and the cleavage of the substrate is started simultaneously when bovine thrombin is added in excess. This excludes interferences by antithrombin III or heparin cofactor II. The change in absorbance/min is recorded at 405 nm. The measuring range is about 0.2 – 4.0 mg/l r-hirudin on both analyzers. Precision is charact…

MaleHirudinEnzyme-Linked Immunosorbent AssayAbsorbanceAutomationReference ValuesBlood plasmamedicineAnimalsHumansHeparin cofactor IIChromatographyChemistryChromogenicAntithrombinThrombinSubstrate (chemistry)Chromogenic substrate assayHematologyHirudinsMiddle AgedRecombinant ProteinsChromogenic CompoundsCalibrationCattleColorimetryFemalePartial Thromboplastin TimeOligopeptidesmedicine.drugThrombosis research
researchProduct

Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.

2012

We report 2 asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0.4% were found in prothrombin time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7 ± 0.2%) which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8 ± 0.9%) and disappeared with rabbit thromboplastin (0.7 ± 0.2%). This suggests that the mutation influences tissue factor/FVII interactions. Whereas the recombinant rFVII-462X variant confirmed an increase in specific activit…

MaleProteasesHeterozygoteFactor VII DeficiencyEnzyme-Linked Immunosorbent AssayFVIIBiologymedicine.disease_causeThromboplastinTissue factorchemistry.chemical_compoundCarboxy-terminalhemic and lymphatic diseasesmedicineFACTOR VII DEFICIENCY MOLECULAR VARIANTSThromboplastinMissense mutationAnimalsHumanscardiovascular diseasesChildBlood CoagulationProthrombin timeMutationmedicine.diagnostic_testFactor VIIHomozygoteHematologyFactor VIIMiddle AgedMolecular biologyAsymptomatic; Carboxy-terminal; FVII; Mutation;AsymptomaticchemistryCoagulationCodon NonsenseMutationMutagenesis Site-DirectedProthrombin TimeCattleFemaleRabbitsOriginal Articles and Brief Reports
researchProduct

Sudden sensorineural hearing loss: is there a relationship between routine haematological parameters and audiogram shapes?

2016

Objective: To investigate the relationship between haematological routine parameters and audiogram shapes in patients affected by sudden sensorineural hearing loss (SSNHL). Design: A retrospective study. All patients were divided into four groups according to the audiometric curve and mean values of haematological parameters (haemoglobin, white blood cell, neutrophils and lymphocytes relative count, platelet count, haematocrit, prothrombin time, activated partial thromboplastin time, fibrinogen and neutrophil-to-lymphocite ratio) of each group were statistically compared. The prognostic role of blood profile and coagulation test was also examined. Study sample: A cohort of 183 SSNHL patient…

MaleTime FactorsNeutrophilshaematological parameterAudiologyLanguage and LinguisticsHemoglobinsLeukocyte Count0302 clinical medicineHearingLymphocytes030223 otorhinolaryngologyHematologic Testsmedicine.diagnostic_testComplete blood countAudiogramSudden sensorineural hearing lossMiddle AgedSettore MED/32 - AudiologiaTreatment OutcomeSettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureHematocrit030220 oncology & carcinogenesisCohortAudiometry Pure-ToneFemalePartial Thromboplastin TimeSteroidsmedicine.symptomPartial thromboplastin timeAdultBlood PlateletsLinguistics and Languagemedicine.medical_specialtyHearing lossHearing Loss Sensorineural03 medical and health sciencesSpeech and HearingAudiogram shapePredictive Value of TestsWhite blood cellmedicineHumansBlood CoagulationRetrospective StudiesProthrombin timePlatelet Countbusiness.industryFibrinogenAuditory ThresholdRetrospective cohort studyRecovery of FunctionHearing Loss Suddenaudiogram shape; haematological parameters; Sudden sensorineural hearing lossProthrombin TimebusinessBiomarkersInternational Journal of Audiology
researchProduct

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the A…

2007

Summary. Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. Patients/methods: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UF…

Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsLipoproteinsMyocardial InfarctionRisk AssessmentSeverity of Illness IndexAngina PectorisThromboplastinCoronary artery diseaseCohort StudiesTissue factor pathway inhibitorPredictive Value of TestsInternal medicineGermanymedicineHumansMyocardial infarctionProspective StudiesAgedProportional Hazards ModelsUnstable anginabusiness.industryHazard ratioCoronary StenosisHematologySyndromeMiddle Agedmedicine.diseasePrognosisThrombosisCardiovascular DiseasesCardiologyFemalebusinessBiomarkersBlood drawingFollow-Up StudiesJournal of thrombosis and haemostasis : JTH
researchProduct

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.

2019

Tissue factor is highly expressed in sub-endothelial tissue. The extracellular allosteric disulfide bond Cys186-Cys209 of human tissue factor shows high evolutionary conservation and in vitro evidence suggests that it significantly contributes to tissue factor procoagulant activity. To investigate the role of this allosteric disulfide bond in vivo, we generated a C213G mutant tissue factor mouse by replacing Cys213 of the corresponding disulfide Cys190-Cys213 in murine tissue factor. A bleeding phenotype was prominent in homozygous C213G tissue factor mice. Pre-natal lethality of 1/3rd of homozygous offspring was observed between E9.5 and E14.5 associated with placental hemorrhages. After b…

Malemedicine.medical_specialtyOffspring610 Medicine & healthHemorrhage030204 cardiovascular system & hematologyBiologymedicine.disease_causeArticleThromboplastin11459 Center for Molecular Cardiology03 medical and health sciencesTissue factorArterial Thrombosis; Blood Coagulation and Fibrinolysis; Disorders of Coagulation and FibrinolysisMice0302 clinical medicineIn vivoPregnancyInternal medicinemedicineExtracellularAnimalsDisulfidesMutationHematologyPhenotypeIn vitroEndocrinologyPhenotype10036 Medical Clinic10076 Center for Integrative Human PhysiologyHemostasisMutation10209 Clinic for CardiologyFemale030215 immunologyHaematologica
researchProduct

Further link between complement activation and blood coagulation

1977

EVIDENCE for interactions between the complement and haemostatic systems has come from two lines of research—blood platelets have been shown to interact with various complement components1–6, and more ambiguous results have been obtained with respect to the role of complement in endotoxin shock and the Shwartzman reaction7–13. We report here that the activated complement component C3b triggers a marked increase of tissue thromboplastin (factor III) activity in cultured human monocytes. Differential counting and nonspecific esterase staining14 of the final preparations regularly revealed more than 85% monocytes.

MultidisciplinaryChemistryComplement C3MonocytesThromboplastinComplement (complexity)Endotoxin shockComplement systemTissue factorCoagulationNonspecific esteraseImmunologyPlateletCycloheximideBlood CoagulationCells CulturedNature
researchProduct

Heparin–polynitroxides: Synthesis and preliminary evaluation as cardiovascular EPR/MR imaging probes and extracellular space-targeted antioxidants

2011

We report here the synthesis of heparin-polynitroxide derivatives (HPNs) in which nitroxide moieties are linked either to uronic acid or glycosamine residues of the heparin macromolecule. HPNs have low anticoagulant activity, possess superoxide scavenging properties, bind to the vascular endothelium/extra-cellular matrix and can be detected by EPR and MRI techniques. As the vascular wall-targeted redox-active paramagnetic compounds, HPNs may have both diagnostic (molecular MRI) and therapeutic (ecSOD mimics) applications.

Nitroxide mediated radical polymerizationmedicine.drug_mechanism_of_actionFactor Xa InhibitorUronic acidAntioxidantslaw.inventionchemistry.chemical_compoundSuperoxideslawDrug DiscoverymedicineExtracellularHumansElectron paramagnetic resonancePharmacologyHeparinSuperoxideOrganic ChemistryElectron Spin Resonance SpectroscopyAnticoagulantsHexosaminesGeneral MedicineHeparinMagnetic Resonance ImagingExtracellular MatrixUronic AcidschemistryBiochemistryMolecular ProbesFactor XaNitrogen OxidesPartial Thromboplastin TimeEndothelium VascularFactor Xa Inhibitorsmedicine.drugMacromoleculeEuropean Journal of Medicinal Chemistry
researchProduct

Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer

2021

Abstract Pancreatic cancer frequently involves cancer‐associated thromboembolism, which is strongly associated with poor prognosis. Tissue factor, a blood coagulation factor largely produced in cancer patients as a component of extracellular vesicles, plays a key role in the incidence of cancer‐associated thromboembolism in patients with pancreatic cancer. However, no prospective studies have been published on the relationship between tissue factor and cancer‐associated thromboembolism or patient clinical characteristics, including recent chemotherapy regimens. Thus, we aimed to address this in a Japanese cohort of 197 patients and 41 healthy volunteers. Plasma tissue factor levels were mea…

OncologyAdultMaleRiskCancer Researchmedicine.medical_specialtyEnzyme-Linked Immunosorbent AssayThromboplastinCohort StudiesTissue factorExtracellular VesiclesJapanClinical ResearchPredictive Value of TestsPancreatic cancerInternal medicineThromboembolismmedicineConfidence IntervalsHumansRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryCancerpancreatic neoplasmGeneral MedicineExtracellular vesicleOriginal ArticlesVenous ThromboembolismMiddle Agedmedicine.diseasetissue factorPancreatic NeoplasmsOncologyrisk factorRelative riskCase-Control StudiesCohortMultivariate AnalysisOriginal ArticleFemaleextracellular vesiclebusinessCancer Science
researchProduct

Manejo perioperatorio de los anticoagulantes orales directos en cirugía urgente y sangrado. Monitorización y tratamiento hemostático

2015

There is an almost unanimous consensus on the management of the direct new oral anticoagulants, dabigatran, rivaroxaban, and apixaban in elective surgery. However, this general consensus does not exist in relation with the direct new oral anticoagulants use in emergency surgery, especially in the bleeding patient. For this reason, a literature review was performed using the MEDLINE-PubMed. An analysis was made of the journal articles, reviews, systematic reviews, and practices guidelines published between 2000 and 2014 using the terms "monitoring" and "reversal". From this review, it was shown that the routine tests of blood coagulation, such as the prothrombin time and activated partial th…

Prothrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryPerioperativeCritical Care and Intensive Care MedicineDabigatranAnesthesiology and Pain MedicineCoagulationAnesthesiamedicineApixabanElective surgerybusinessmedicine.drugPartial thromboplastin timeRevista Española de Anestesiología y Reanimación
researchProduct

The impact of whole blood processing and freezing conditions on the quality of therapeutic plasma prepared from whole blood

2014

Background The quality of whole blood (WB)-derived plasma preparations has been the subject of several studies, but there has been a lack of robust, comparative data for the different methods of processing and freezing. Study Design and Methods Six WB-derived plasma units were pooled and split (n = 16) and frozen within either 8 or 24 hours after WB collection, stored at 4°C or at room temperature (RT), and then frozen either slowly at −20°C or rapidly to below −30°C. Plasma units were tested for fibrinogen, Factor (F)V, FVII, FVIII, FXI, and von Willebrand factor (VWF), protein C (PC), protein S (PS) activity and free PS, prothrombin time, and partial thromboplastin time. Results FVIII was…

Prothrombin timemedicine.medical_specialtymedicine.diagnostic_testbiologyChemistryImmunologyHematologyPlasmaFibrinogenProtein SSurgeryAndrologyVon Willebrand factorhemic and lymphatic diseasesmedicinebiology.proteinImmunology and AllergyProtein CWhole bloodmedicine.drugPartial thromboplastin timeTransfusion
researchProduct